테노포비르 디소프록실 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "테노포비르 디소프록실" in Korean language version.

refsWebsite

Global rank Korean rank

12web.archive.org

1^st place

11nih.gov

4^th place

9doi.org

2^nd place

3^rd place

3semanticscholar.org

11^th place

310^th place

2fda.gov

447^th place

433^rd place

1drugs.com

399^th place

141^st place

1handle.net

102^nd place

307^th place

1tevapharm.com

low place

1gilead.com

low place

1theconversation.com

928^th place

1,005^th place

1medlineplus.gov

1,581^st place

1,462^nd place

1harvard.edu

18^th place

27^th place

1drugbank.ca

4,294^th place

1,811^th place

1google.com

163^rd place

63^rd place

1espacenet.com

800^th place

1,296^th place

1wsj.com

79^th place

200^th place

1who.int

195^th place

98^th place

doi.org

dx.doi.org

Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Okwundu CI, Uthman OA, Okoromah CA (July 2012). “Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals”. 《The Cochrane Database of Systematic Reviews》 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMID 22786505.
Ustianowski A, Arends JE (June 2015). “Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use”. 《Infectious Diseases and Therapy》 4 (2): 145–57. doi:10.1007/s40121-015-0070-1. PMC 4471058. PMID 26032649.
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G (2013년 6월 12일). “Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012”. 《PLOS ONE》 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO (September 1998). “Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults”. 《Antimicrobial Agents and Chemotherapy》 42 (9): 2380–4. doi:10.1128/aac.42.9.2380. PMC 105837. PMID 9736567.
Mouton JP, Cohen K, Maartens G (November 2016). “Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen”. 《Expert Review of Clinical Pharmacology》 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.
Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (November 2006). “Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention”. 《AIDS Research and Therapy》 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170.
Delahunty T, Bushman L, Robbins B, Fletcher CV (July 2009). “The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards”. 《Journal of Chromatography B》 877 (20–21): 1907–14. doi:10.1016/j.jchromb.2009.05.029. PMC 2714254. PMID 19493710.
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.

drugbank.ca

Drugbank: Tenofovir 보관됨 2015-09-08 - 웨이백 머신

drugs.com

“Tenofovir Disoproxil Fumarate”. The American Society of Health-System Pharmacists. 2016년 11월 30일에 원본 문서에서 보존된 문서. 2016년 11월 29일에 확인함.

espacenet.com

worldwide.espacenet.com

A US 4724233 A, De Clercq, Erik; Antonin Holy & Ivan Rosenberg, "Therapeutical application of phosphonylmethoxyalkyl adenines"

fda.gov

FDA letter of approval (regarding treatment of hepatitis B) 보관됨 2009-02-25 - 웨이백 머신

accessdata.fda.gov

“Drugs@FDA: FDA Approved Drug Products”. 《www.accessdata.fda.gov》. 2016년 11월 10일에 원본 문서에서 보존된 문서. 2016년 11월 9일에 확인함.

gilead.com

Gilead Sciences, Inc. Prescribing Information. 보관됨 2013-02-07 - 웨이백 머신 Revised: November 2012.

google.com

“Patent US4808716 - 9-(phosponylmethoxyalkyl) adenines, the method of preparation and ... - Google Patents”. 2014년 5월 9일에 원본 문서에서 보존된 문서.

handle.net

hdl.handle.net

World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

adsabs.harvard.edu

Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G (2013년 6월 12일). “Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012”. 《PLOS ONE》 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.

medlineplus.gov

“Tenofovir: MedlinePlus Drug Information”. 《medlineplus.gov》. 2016년 11월 10일에 원본 문서에서 보존된 문서. 2016년 11월 9일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Okwundu CI, Uthman OA, Okoromah CA (July 2012). “Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals”. 《The Cochrane Database of Systematic Reviews》 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMID 22786505.
Ustianowski A, Arends JE (June 2015). “Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use”. 《Infectious Diseases and Therapy》 4 (2): 145–57. doi:10.1007/s40121-015-0070-1. PMC 4471058. PMID 26032649.
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G (2013년 6월 12일). “Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012”. 《PLOS ONE》 8 (6): e66223. Bibcode:2013PLoSO...866223M. doi:10.1371/journal.pone.0066223. PMC 3680439. PMID 23776637.
Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO (September 1998). “Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults”. 《Antimicrobial Agents and Chemotherapy》 42 (9): 2380–4. doi:10.1128/aac.42.9.2380. PMC 105837. PMID 9736567.
Mouton JP, Cohen K, Maartens G (November 2016). “Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen”. 《Expert Review of Clinical Pharmacology》 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.
Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (November 2006). “Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention”. 《AIDS Research and Therapy》 3: 29. doi:10.1186/1742-6405-3-29. PMC 1687192. PMID 17132170.
Delahunty T, Bushman L, Robbins B, Fletcher CV (July 2009). “The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards”. 《Journal of Chromatography B》 877 (20–21): 1907–14. doi:10.1016/j.jchromb.2009.05.029. PMC 2714254. PMID 19493710.
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.

pubchem.ncbi.nlm.nih.gov

Pubchem. “Tenofovir disoproxil”. 《pubchem.ncbi.nlm.nih.gov》 (영어). 2018년 4월 17일에 확인함.

aidsinfo.nih.gov

“AIDSinfo Drug Database: Tenofovir disoproxil fumarate”. National Institutes of Health. 2017년 4월 28일에 원본 문서에서 보존된 문서. 2016년 8월 4일에 확인함.

semanticscholar.org

api.semanticscholar.org

Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.
Mouton JP, Cohen K, Maartens G (November 2016). “Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen”. 《Expert Review of Clinical Pharmacology》 9 (11): 1493–1503. doi:10.1080/17512433.2016.1221760. PMID 27498720. S2CID 205930751.
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006). “Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. 《Clinical Pharmacokinetics》 45 (11): 1115–24. doi:10.2165/00003088-200645110-00005. PMID 17048975. S2CID 6322957.

tevapharm.com

“Teva Announces Exclusive Launch of a Generic version of Viread in the United States”. 《www.tevapharm.com》. 2018년 11월 6일에 원본 문서에서 보존된 문서. 2021년 6월 23일에 확인함.

theconversation.com

Emma Bourke (2013년 6월 14일). “Preventive drug could reduce HIV transmission among injecting drug users”. 《The Conversation Australia》. The Conversation Media Group. 2013년 11월 1일에 원본 문서에서 보존된 문서. 2013년 6월 17일에 확인함.

web.archive.org

“Tenofovir Disoproxil Fumarate”. The American Society of Health-System Pharmacists. 2016년 11월 30일에 원본 문서에서 보존된 문서. 2016년 11월 29일에 확인함.
“Teva Announces Exclusive Launch of a Generic version of Viread in the United States”. 《www.tevapharm.com》. 2018년 11월 6일에 원본 문서에서 보존된 문서. 2021년 6월 23일에 확인함.
Gilead Sciences, Inc. Prescribing Information. 보관됨 2013-02-07 - 웨이백 머신 Revised: November 2012.
Emma Bourke (2013년 6월 14일). “Preventive drug could reduce HIV transmission among injecting drug users”. 《The Conversation Australia》. The Conversation Media Group. 2013년 11월 1일에 원본 문서에서 보존된 문서. 2013년 6월 17일에 확인함.
“Tenofovir: MedlinePlus Drug Information”. 《medlineplus.gov》. 2016년 11월 10일에 원본 문서에서 보존된 문서. 2016년 11월 9일에 확인함.
Drugbank: Tenofovir 보관됨 2015-09-08 - 웨이백 머신
“Patent US4808716 - 9-(phosponylmethoxyalkyl) adenines, the method of preparation and ... - Google Patents”. 2014년 5월 9일에 원본 문서에서 보존된 문서.
FDA letter of approval (regarding treatment of hepatitis B) 보관됨 2009-02-25 - 웨이백 머신
FDA Clears Viread for Hepatitis B 보관됨 2017-09-08 - 웨이백 머신
“Drugs@FDA: FDA Approved Drug Products”. 《www.accessdata.fda.gov》. 2016년 11월 10일에 원본 문서에서 보존된 문서. 2016년 11월 9일에 확인함.
“AIDSinfo Drug Database: Tenofovir disoproxil fumarate”. National Institutes of Health. 2017년 4월 28일에 원본 문서에서 보존된 문서. 2016년 8월 4일에 확인함.
“Tenofovir disoproxil fumarate” (PDF). World Health Organization. June 2010. 2016년 8월 8일에 원본 문서 (PDF)에서 보존된 문서.

who.int

“Tenofovir disoproxil fumarate” (PDF). World Health Organization. June 2010. 2016년 8월 8일에 원본 문서 (PDF)에서 보존된 문서.

wsj.com

FDA Clears Viread for Hepatitis B 보관됨 2017-09-08 - 웨이백 머신